These measures apply only to patients with NSTEMI. ACC indicates American College of Cardiology; ACEI, angiotensin-converting enzyme inhibitor; AHA, American Heart Association; ARB, angiotensin receptor blocker; ED, emergency department; FMC, first medical contact; LVEF, left ventricular ejection fraction; LVSD, left ventricular systolic dysfunction; NSAIDs, nonsteroidal anti- inflammatory drugs; NSTEMI, non ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; PM, performance measures; QM, quality measures; STEMI, ST-elevation myocardial infarction; and TIA, transient ischemic attack. 5 selected to serve as peer reviewers of this document, were required to disclose all current relationships and those exist- ing within the 12 months before the initiation of this writing effort. ACC/AHA policy also requires that the writing com- mittee chairs and at least 50% of the writing committee have no relevant RWI. Any writing committee member who develops new RWI during his or her tenure on the writing committee is required to notify staff in writing. These statements are reviewed peri- odically by the Task Force and by members of the writing committee. Author and peer reviewer RWI which are rele- vant to the document are included in the appendixes: Please see Appendix B for relevant writing committee RWI and Appendix C for relevant peer reviewer RWI. Additionally, to ensure complete transparency, the writing committee mem- bers comprehensive disclosure information, including RWI not relevant to the present document, is available online. Disclosure information for the Task Force is also available online. The work of the writing committee was supported exclu- sively by the ACC and the AHA without commercial support. Members of the writing committee volunteered their time for this effort. 